Jawahar Sudhamsu

Jawahar Sudhamsu

Auto-generated profile, based on publicly available information

Jawahar Sudhamsu

Department of Structural Biology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2021 in Nature
Verified
Journal Article
Closed access
PDF file
IYIvana Yen
Ivana Yen
FSFrances Shanahan
Frances Shanahan
JLJeeyun Lee
Jeeyun Lee
YHYong Sang Hong
Yong Sang Hong
SSSang Joon Shin
Sang Joon Shin
SMShiva Malek
Shiva Malek

8 September 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
NSNicole M. Sodir
Nicole M. Sodir
GPGaurav Pathria
Gaurav Pathria
JAJoanne I. Adamkewicz
Joanne I. Adamkewicz
EKElizabeth H. Kelley
Elizabeth H. Kelley
JSJawahar Sudhamsu
Jawahar Sudhamsu
DMDanilo Maddalo
Danilo Maddalo
The protein phosphatase SHP2/PTPN11 has been reported to be a key modulator of proliferative pathways in a wide range of malignancies. Intriguingly, SHP2 has also been described as a critical regulator of the tumor microenvironment. Based on this evidence SHP2 is considered a multifaceted target in cancer, spurring the notion that the development of direct inhibitors of SHP2 would provide the twofold benefit of tumor intrinsic and extrinsic inhibition. In this review, we will discuss the role of SHP2 in cancer and the tumor microenvironment, and the clinical strategies in which SHP2 inhibitors are leveraged as combination agents to improve therapeutic response. Significance: The SHP2 phosphatase functions as a pleiotropic factor, and its inhibition not only hinders tumor growth but also reshapes the tumor microenvironment. Although their single-agent activity may be limited, SHP2 inhibitors hold the potential of being key combination agents to enhance the depth and the durability of tumor response to therapy.

27 January 2020 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
NLNicholas Liau
Nicholas Liau
TWTimothy J. Wendorff
Timothy J. Wendorff
JQJohn G. Quinn
John G. Quinn
MSMicah Steffek
Micah Steffek
WPWilson Phung
Wilson Phung
JSJawahar Sudhamsu
Jawahar Sudhamsu

29 June 2022 in Nature
Verified
Journal Article
Open access
PDF file
NLNicholas P. D. Liau
Nicholas P. D. Liau
MJMatthew C. Johnson
Matthew C. Johnson
SISaeed Izadi
Saeed Izadi
LGLuca Gerosa
Luca Gerosa
MHMichal Hammel
Michal Hammel
JSJawahar Sudhamsu
Jawahar Sudhamsu
The RAS–RAF pathway is one of the most commonly dysregulated in human cancers1–3. Despite decades of study, understanding of the molecular mechanisms underlying dimerization and activation4of the kinase RAF remains limited. Recent structures of inactive RAF monomer5and active RAF dimer5–8bound to 14-3-39,10have revealed the mechanisms by which 14-3-3 stabilizes both RAF conformations via specific phosphoserine residues. Prior to RAF dimerization, the protein phosphatase 1 catalytic subunit (PP1C) must dephosphorylate the N-terminal phosphoserine (NTpS) of RAF11to relieve inhibition by 14-3-3, although PP1C in isolation lacks intrinsic substrate selectivity. SHOC2 is as an essential scaffolding protein that engages both PP1C and RAS to dephosphorylate RAF NTpS11–13, but the structure of SHOC2 and the architecture of the presumptive SHOC2–PP1C–RAS complex remain unknown. Here we present a cryo-electron microscopy structure of the SHOC2–PP1C–MRAS complex to an overall resolution of 3 Å, revealing a tripartite molecular architecture in which a crescent-shaped SHOC2 acts as a cradle and brings together PP1C and MRAS. Our work demonstrates the GTP dependence of multiple RAS isoforms for complex formation, delineates the RAS-isoform preference for complex assembly, and uncovers how the SHOC2 scaffold and RAS collectively drive specificity of PP1C for RAF NTpS. Our data indicate that disease-relevant mutations affect complex assembly, reveal the simultaneous requirement of two RAS molecules for RAF activation, and establish rational avenues for discovery of new classes of inhibitors to target this pathway.

14 December 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
JCJoseph Chavarria-Smith
Joseph Chavarria-Smith
CCCecilia P.C. Chiu
Cecilia P.C. Chiu
JJJanet K. Jackman
Janet K. Jackman
JYJianping Yin
Jianping Yin
JZJuan Zhang
Juan Zhang
TYTangsheng Yi
Tangsheng Yi
The epidermis is a barrier that prevents water loss while keeping harmful substances from penetrating the host. The impermeable cornified layer of the stratum corneum is maintained by balancing continuous turnover driven by epidermal basal cell proliferation, suprabasal cell differentiation, and corneal shedding. The epidermal desquamation process is tightly regulated by balance of the activities of serine proteases of the Kallikrein-related peptidases (KLK) family and their cognate inhibitor lymphoepithelial Kazal type–related inhibitor (LEKTI), which is encoded by the serine peptidase inhibitor Kazal type 5 gene. Imbalance of proteolytic activity caused by a deficiency of LEKTI leads to excessive desquamation due to increased activities of KLK5, KLK7, and KLK14 and results in Netherton syndrome (NS), a debilitating condition with an unmet clinical need. Increased activity of KLKs may also be pathological in other dermatoses such as atopic dermatitis (AD). Here, we describe the discovery of inhibitory antibodies against murine KLK5 and KLK7 that could compensate for the deficiency of LEKTI in NS. These antibodies are protective in mouse models of NS and AD and, when combined, promote improved skin barrier integrity and reduced inflammation. To translate these findings, we engineered a humanized bispecific antibody capable of potent inhibition of human KLK5 and KLK7. A crystal structure of KLK5 bound to the inhibitory Fab revealed that the antibody binds distal to its active site and uses a relatively unappreciated allosteric inhibition mechanism. Treatment with the bispecific anti-KLK5/7 antibody represents a promising therapy for clinical development in NS and other inflammatory dermatoses.

8 February 2022 in Cell Reports
Verified
Journal Article
Open access
AVAvinashnarayan Venkatanarayan
Avinashnarayan Venkatanarayan
JLJason Liang
Jason Liang
IYIvana Yen
Ivana Yen
FSFrances Shanahan
Frances Shanahan
BHBenjamin Haley
Benjamin Haley
SMShiva Malek
Shiva Malek
KRAS, which is mutated in ∼30% of all cancers, activates the RAF-MEK-ERK signaling cascade. CRAF is required for growth of KRAS mutant lung tumors, but the requirement for CRAF kinase activity is unknown. Here, we show that subsets of KRAS mutant tumors are dependent on CRAF for growth. Kinase-dead but not dimer-defective CRAF rescues growth inhibition, suggesting that dimerization but not kinase activity is required. Quantitative proteomics demonstrates increased levels of CRAF:ARAF dimers in KRAS mutant cells, and depletion of both CRAF and ARAF rescues the CRAF-loss phenotype. Mechanistically, CRAF depletion causes sustained ERK activation and induction of cell-cycle arrest, while treatment with low-dose MEK or ERK inhibitor rescues the CRAF-loss phenotype. Our studies highlight the role of CRAF in regulating MAPK signal intensity to promote tumorigenesis downstream of mutant KRAS and suggest that disrupting CRAF dimerization or degrading CRAF may have therapeutic benefit.